Cargando…
Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study
BACKGROUND: For chronic hepatitis C (CHC) patients completing pegylated interferon (PegIFN)-α/ribavirin therapy, long-term liver histological changes remain largely unexplored. METHODS: This observational cohort study included 85 CHC patients completing PegIFN-α/ribavirin therapy with liver biopsies...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771741/ https://www.ncbi.nlm.nih.gov/pubmed/35070254 http://dx.doi.org/10.1177/20406223211067631 |
_version_ | 1784635679066554368 |
---|---|
author | Hsieh, Ming-Han Kao, Tzu-Yu Hsieh, Ting-Hui Kao, Chun-Chi Peng, Cheng-Yuan Lai, Hsueh-Chou Chuang, Po-Heng Kao, Jung-Ta |
author_facet | Hsieh, Ming-Han Kao, Tzu-Yu Hsieh, Ting-Hui Kao, Chun-Chi Peng, Cheng-Yuan Lai, Hsueh-Chou Chuang, Po-Heng Kao, Jung-Ta |
author_sort | Hsieh, Ming-Han |
collection | PubMed |
description | BACKGROUND: For chronic hepatitis C (CHC) patients completing pegylated interferon (PegIFN)-α/ribavirin therapy, long-term liver histological changes remain largely unexplored. METHODS: This observational cohort study included 85 CHC patients completing PegIFN-α/ribavirin therapy with liver biopsies performed at baseline and the end of surveillance (EOS). Median years between paired biopsies were 6.75 (interquartile range: 5.63–7.54). RESULTS: In patients with baseline METAVIR fibrosis stages (F) <4 (able to undergo fibrosis progression; n = 77), cases achieving sustained virological response (SVR) (n = 52) had a significantly lower rate of fibrosis progression than non-SVR cases (n = 25) (3.8% versus 24.0%, p = 0.012). Among the entire cohort (n = 85), the rate of activity response [METAVIR activity grades (A) decreasing or maintaining at A0] in SVR cases (n = 59) was significantly higher than that in non-SVR cases (n = 26) (94.9% versus 65.4%, p = 0.001). For SVR cases among the entire cohort, independent predictors of fibrosis clearance included baseline F <2 [odds ratio (OR) = 7.877, p = 0.042] and aspartate transaminase (AST) levels declining by >70% at EOS compared with baseline (OR = 9.013, p = 0.038). For non-SVR cases among the entire cohort, baseline AST levels >80 U/l and glucose levels ⩽ 105 mg/dl independently predicted significant fibrosis (F2/F3/F4) at EOS (OR = 12.558, p = 0.049) and activity response (OR = 17.741, p = 0.047), respectively. CONCLUSIONS: Among CHC patients completing PegIFN-α/ribavirin therapy, SVR lowers the risk of liver histological progression but does not guarantee fibrosis clearance. For SVR cases, those with baseline F ⩾ 2 or without significantly declined follow-up AST levels should be specifically monitored. As for non-SVR cases, those with a higher baseline AST or glucose level should preferentially receive retreatment. |
format | Online Article Text |
id | pubmed-8771741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-87717412022-01-21 Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study Hsieh, Ming-Han Kao, Tzu-Yu Hsieh, Ting-Hui Kao, Chun-Chi Peng, Cheng-Yuan Lai, Hsueh-Chou Chuang, Po-Heng Kao, Jung-Ta Ther Adv Chronic Dis Original Research BACKGROUND: For chronic hepatitis C (CHC) patients completing pegylated interferon (PegIFN)-α/ribavirin therapy, long-term liver histological changes remain largely unexplored. METHODS: This observational cohort study included 85 CHC patients completing PegIFN-α/ribavirin therapy with liver biopsies performed at baseline and the end of surveillance (EOS). Median years between paired biopsies were 6.75 (interquartile range: 5.63–7.54). RESULTS: In patients with baseline METAVIR fibrosis stages (F) <4 (able to undergo fibrosis progression; n = 77), cases achieving sustained virological response (SVR) (n = 52) had a significantly lower rate of fibrosis progression than non-SVR cases (n = 25) (3.8% versus 24.0%, p = 0.012). Among the entire cohort (n = 85), the rate of activity response [METAVIR activity grades (A) decreasing or maintaining at A0] in SVR cases (n = 59) was significantly higher than that in non-SVR cases (n = 26) (94.9% versus 65.4%, p = 0.001). For SVR cases among the entire cohort, independent predictors of fibrosis clearance included baseline F <2 [odds ratio (OR) = 7.877, p = 0.042] and aspartate transaminase (AST) levels declining by >70% at EOS compared with baseline (OR = 9.013, p = 0.038). For non-SVR cases among the entire cohort, baseline AST levels >80 U/l and glucose levels ⩽ 105 mg/dl independently predicted significant fibrosis (F2/F3/F4) at EOS (OR = 12.558, p = 0.049) and activity response (OR = 17.741, p = 0.047), respectively. CONCLUSIONS: Among CHC patients completing PegIFN-α/ribavirin therapy, SVR lowers the risk of liver histological progression but does not guarantee fibrosis clearance. For SVR cases, those with baseline F ⩾ 2 or without significantly declined follow-up AST levels should be specifically monitored. As for non-SVR cases, those with a higher baseline AST or glucose level should preferentially receive retreatment. SAGE Publications 2022-01-13 /pmc/articles/PMC8771741/ /pubmed/35070254 http://dx.doi.org/10.1177/20406223211067631 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Hsieh, Ming-Han Kao, Tzu-Yu Hsieh, Ting-Hui Kao, Chun-Chi Peng, Cheng-Yuan Lai, Hsueh-Chou Chuang, Po-Heng Kao, Jung-Ta Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study |
title | Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study |
title_full | Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study |
title_fullStr | Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study |
title_full_unstemmed | Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study |
title_short | Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study |
title_sort | long-term surveillance of liver histological changes in chronic hepatitis c patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771741/ https://www.ncbi.nlm.nih.gov/pubmed/35070254 http://dx.doi.org/10.1177/20406223211067631 |
work_keys_str_mv | AT hsiehminghan longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy AT kaotzuyu longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy AT hsiehtinghui longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy AT kaochunchi longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy AT pengchengyuan longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy AT laihsuehchou longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy AT chuangpoheng longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy AT kaojungta longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy |